Jazz Pharmaceuticals (JAZZ) Wells Fargo 21st Annual Healthcare Conference summary

Commercial performance and portfolio execution

• Achieved record Q2 revenue of $1.2 billion, representing 16% growth, with double-digit growth across all key brands.

• Xywav demonstrated resilience against generic entrants, with strong demand and continued patient growth, especially due to its low-sodium profile.

• Rylaze and ZEPZELCA launches contributed significantly, with ZEPZELCA's first-line maintenance segment now accounting for 30%-40% of revenue.

• EPIDIOLEX saw 16% revenue and 14% volume growth, driven by expansion into adult segments and new formulation development.

• Modeyso annualized at $200 million in second-line use, with further growth expected from improved testing and upcoming clinical data.

Pipeline, launches, and future growth drivers

• Ziihera's GEA launch is supported by unprecedented survival data, with peak sales potential raised to $3–$5 billion, and expansion planned into multiple tumor types.

• Ongoing clinical programs for EPIDIOLEX target new epilepsy indications, leveraging a longer exclusivity runway.

• Modeyso's growth is expected to accelerate with the ACTION study readout in 2027, enabling earlier patient eligibility.

• ZEPZELCA's focus has shifted to first-line maintenance, with anticipated continued growth despite increasing competition.

• Actio Biosciences acquisition brings a promising rare epilepsy asset, with strong commercial synergies expected alongside EPIDIOLEX.

Market dynamics and competitive landscape

• Xywav's differentiation from generics is driven by its low-sodium formulation, maintaining physician preference.

• Orexins are seen as complementary rather than direct competitors, with both agents potentially used in combination for narcolepsy and IH.

• IH market remains underpenetrated, with only 9,000 treated out of an estimated 100,000 patients, offering significant growth runway.

• Ziihera's commercial launch benefits from existing prescriber overlap and minimal payer friction, aiming for rapid uptake.

• Business development remains focused on rare diseases in epilepsy, sleep, and oncology, with a disciplined approach to new transactions.